Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT)

Página do item simplificado
dc.contributor.authorACT Investigators
dc.contributor.authorTura, Bernardo R
dc.contributor.authorSantos Junior, Bráulio dos
dc.contributor.authorCramer, Helena
dc.date.accessioned2024-01-05T12:47:19Z
dc.date.available2024-01-05T12:47:19Z
dc.date.issued2011
dc.description.abstractBackground: It remains uncertain whether acetylcysteine prevents contrast-induced acute kidney injury. Methods and results: We randomly assigned 2308 patients undergoing an intravascular angiographic procedure with at least 1 risk factor for contrast-induced acute kidney injury (age >70 years, renal failure, diabetes mellitus, heart failure, or hypotension) to acetylcysteine 1200 mg or placebo. The study drugs were administered orally twice daily for 2 doses before and 2 doses after the procedure. The allocation was concealed (central Web-based randomization). All analysis followed the intention-to-treat principle. The incidence of contrast-induced acute kidney injury (primary end point) was 12.7% in the acetylcysteine group and 12.7% in the control group (relative risk, 1.00; 95% confidence interval, 0.81 to 1.25; P=0.97). A combined end point of mortality or need for dialysis at 30 days was also similar in both groups (2.2% and 2.3%, respectively; hazard ratio, 0.97; 95% confidence interval, 0.56 to 1.69; P=0.92). Consistent effects were observed in all subgroups analyzed, including those with renal impairment. Conclusions: In this large randomized trial, we found that acetylcysteine does not reduce the risk of contrast-induced acute kidney injury or other clinically relevant outcomes in at-risk patients undergoing coronary and peripheral vascular angiography. Clinical trial registration: http://www.clinicaltrials.gov. Unique identifier: NCT00736866.
dc.identifier.citationACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011 Sep 13;124(11):1250-9. doi: 10.1161/CIRCULATIONAHA.111.038943.
dc.identifier.otherDOI: 10.1161/CIRCULATIONAHA.111.038943
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/389
dc.language.isoen
dc.publisherCirculation
dc.subject.meshAcetylcysteine / therapeutic useen
dc.subject.meshAcute Kidney Injury / chemically induceden
dc.subject.meshAcute Kidney Injury / prevention & controlen
dc.subject.meshAgeden
dc.subject.meshContrast Media / adverse effectsen
dc.subject.meshCoronary Angiography / adverse effectsen
dc.subject.meshCoronary Angiography / methodsen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshKidney Diseases / chemically induceden
dc.subject.meshKidney Diseases / prevention & controlen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshRandomized Controlled Trials as Topic / methodsen
dc.subject.meshTreatment Outcomeen
dc.titleAcetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT)
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Tura BR et al_Circulation_ARTIGO RESTRITO.pdf
Tamanho:
229.03 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar
Coleções
Produção Docente
Artigos Mestrado CC